133 related articles for article (PubMed ID: 38429120)
1. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment.
Qiao J; Liu S; Huang Y; Zhu X; Xue C; Wang Y; Xiong H; Yao J
J Colloid Interface Sci; 2024 Jul; 665():477-490. PubMed ID: 38429120
[TBL] [Abstract][Full Text] [Related]
2. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
3. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
[TBL] [Abstract][Full Text] [Related]
4. KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.
Althaiban A; Thyagarajan A; Sahu RP
Mini Rev Med Chem; 2023; 23(8):953-961. PubMed ID: 36573057
[TBL] [Abstract][Full Text] [Related]
5. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
[TBL] [Abstract][Full Text] [Related]
6. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
[TBL] [Abstract][Full Text] [Related]
7. Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRAS
Tan YQ; Sun B; Zhang X; Zhang S; Guo H; Basappa B; Zhu T; Sethi G; Lobie PE; Pandey V
Cell Death Dis; 2024 Feb; 15(2):173. PubMed ID: 38409090
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
[TBL] [Abstract][Full Text] [Related]
9. Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma.
Rajpurohit T; Bhattacharya S
Curr Mol Pharmacol; 2022; 15(7):904-928. PubMed ID: 35088684
[TBL] [Abstract][Full Text] [Related]
10. Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer.
Mortazavi M; Moosavi F; Martini M; Giovannetti E; Firuzi O
Crit Rev Oncol Hematol; 2022 Aug; 176():103749. PubMed ID: 35728737
[TBL] [Abstract][Full Text] [Related]
11. ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells.
Khandakar GI; Satoh R; Takasaki T; Fujitani K; Tanabe G; Sakai K; Nishio K; Sugiura R
Cells; 2022 Feb; 11(4):. PubMed ID: 35203351
[TBL] [Abstract][Full Text] [Related]
12. Elevated FBXL6 activates both wild-type KRAS and mutant KRAS
Xiong HJ; Yu HQ; Zhang J; Fang L; Wu D; Lin XT; Xie CM
Mil Med Res; 2023 Dec; 10(1):68. PubMed ID: 38124228
[TBL] [Abstract][Full Text] [Related]
13. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
Venkannagari S; Fiskus W; Peth K; Atadja P; Hidalgo M; Maitra A; Bhalla KN
Oncotarget; 2012 Nov; 3(11):1416-27. PubMed ID: 23232026
[TBL] [Abstract][Full Text] [Related]
14. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
15. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
[TBL] [Abstract][Full Text] [Related]
16. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity for Kras
Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
[TBL] [Abstract][Full Text] [Related]
18. The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Al-Ali R; Krake S; Radefeldt M; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457111
[TBL] [Abstract][Full Text] [Related]
19. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.
Totiger TM; Srinivasan S; Jala VR; Lamichhane P; Dosch AR; Gaidarski AA; Joshi C; Rangappa S; Castellanos J; Vemula PK; Chen X; Kwon D; Kashikar N; VanSaun M; Merchant NB; Nagathihalli NS
Mol Cancer Ther; 2019 Feb; 18(2):301-311. PubMed ID: 30404927
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
Adamopoulos C; Cave DD; Papavassiliou AG
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
